SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 or 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
Report on Form 6-K dated November 21, 2008
(Commission File No. 1-15024)
Novartis AG
(Name of Registrant)
Lichtstrasse 35
4056 Basel
Switzerland
(Address of Principal Executive Offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F: x Form 40-F: o
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Yes: o No: x
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
Yes: o No: x
Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes: o No: x
|
|
|
Novartis International AG Novartis Global Communications CH-4002 Basel Switzerland http://www.novartis.com |
- Investor Relations Release -
Rasilez HCT® receives recommendation for European approval as a single-pill combination to treat high blood pressure
· Combination of first-in-class direct renin inhibitor Rasilez® with the diuretic HCT is twice as effective at reducing blood pressure compared to HCT alone(1)
· 80% of patients may need multiple medicines to reach blood pressure goals; single-pill combinations offer convenience and simplify treatment regimens(2)
· High blood pressure affects 60% more people in Europe than North America; it is the main risk factor for stroke, which claims 650,000 lives in Europe per year(3)
· Positive CHMP opinion follows Swiss and US approvals of Rasilez/Tekturna HCT; European Commission decision expected in early 2009
Basel, November 21, 2008 — Rasilez HCT® (aliskiren and hydrochlorothiazide) received a positive opinion from the European Committee for Medicinal Products for Human Use (CHMP) recommending marketing authorization as a new treatment for high blood pressure. Rasilez HCT is a single-pill combination of two high blood pressure medicines – first-in-class direct renin inhibitor Rasilez®(1) (aliskiren) and the diuretic hydrochlorothiazide (HCT).
Rasilez HCT is twice as effective at reducing high blood pressure compared to HCT alone(1). Rasilez, known as Tekturna® in the US, has been shown to consistently lower blood pressure beyond 24 hours(4),(5). HCT, sometimes called a “water pill”, is one of the most commonly used high blood pressure medicines(2).
Approximately 80% of patients require two or more medications to control their high blood pressure(2). Single-pill combinations may offer patients with high blood pressure convenience and simplify treatment regimens(2).
One in four adults worldwide suffers from high blood pressure(2). The prevalence of high blood pressure is 60% higher in Europe compared to North America and is the main risk factor for stroke, which claims 650,000 lives in Europe per year(3).
“Many patients who are suffering from high blood pressure are still not achieving their treatment goals. Therefore, it is critical that we continue to offer treatments that are effective and convenient,” said Professor Rainer Düsing, MD, Faculty of Medicine, University of Bonn. “Studies
(1) Rasilez® is the trade name for aliskiren throughout the world, except in the US where it is known as Tekturna®.
2
have shown that single-pill combinations may increase treatment adherence by up to 20% compared to free dose combinations of the same treatments. Rasilez HCT offers effective blood pressure lowering medications in one single pill – helping patients gain better control of their high blood pressure with the convenience of having to take only one pill.”
The positive CHMP opinion recommends Rasilez HCT for use in patients not controlled by either medicine alone and for patients who are adequately controlled using Rasilez and HCT as separate medicines with the same dosing regimen offered in the single-pill combination. The opinion was based on clinical trials involving more than 2,700 patients and follows recent Swissmedic approval of Rasilez HCT and US Food and Drug Administration (FDA) approval in the US where it is known as Tekturna HCT®(6),(7).
“It is clear that patients with high blood pressure can benefit from more convenient treatment options that are effective and well tolerated,” said Trevor Mundel, MD, Head of Global Development Functions at Novartis Pharma AG. “The complementary action of a direct renin inhibitor and a diuretic provides twice as much blood pressure lowering compared to the diuretic alone with the convenience of having to take only a single-pill. We are very pleased that the CHMP recognizes the beneficial value of Rasilez HCT and look forward to the European Commission decision in early 2009.”
The heart and kidney protection potential of Rasilez/Tekturna, independent of its blood pressure lowering ability, is currently being investigated further in the landmark ASPIRE HIGHER program, the largest ongoing cardio-renal outcomes program worldwide involving more than 35,000 patients in 14 trials.
Rasilez/Tekturna is approved in 57 countries. Tekturna was approved in the US in March 2007 and in the European Union in August 2007 under the trade name Rasilez. Rasilez HCT was approved in Switzerland in October 2008 and a European Commission decision is expected for the single-pill combination in early 2009. Tekturna HCT, the first single-pill combination involving Tekturna, was approved in the US in January 2008.
Novartis is focused on improving the lives of the hundreds of millions of people with cardiovascular and metabolic diseases. As a global leader in cardiovascular and metabolic health for nearly 50 years, Novartis provides innovative therapies and support programs to treat high blood pressure and diabetes – both major public health issues. The portfolio includes the world’s most-prescribed angiotensin receptor blocker, the first and only approved direct renin inhibitor, a single pill combining two leading high blood pressure medicines, and a novel DPP-4 inhibitor. Novartis is dedicated to helping physicians and patients through effective medicines, programs and an ongoing commitment to research.
Disclaimer
The foregoing release contains forward-looking statements that can be identified by terminology such as “recommendation,” “may,” “risk,” “expected,” “recommending,” “recommends,” “can,” “look forward,” “potential,” “expected,” or similar expressions, or by express or implied discussions regarding potential marketing approvals for Rasilez HCT or regarding potential future revenues from Rasilez or Rasilez HCT. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results with Rasilez or Rasilez HCT to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that Rasilez HCT will be approved for sale in any market. Nor can there be any guarantee that Rasilez or Rasilez HCT will achieve any particular levels of revenue in the future. In particular, management’s
3
expectations regarding Rasilez or Rasilez HCT could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; competition in general; government, industry and general public pricing pressures; the company’s ability to obtain or maintain patent or other proprietary intellectual property protection; the impact that the foregoing factors could have on the values attributed to the Novartis Group’s assets and liabilities as recorded in the Group’s consolidated balance sheet, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
About Novartis
Novartis AG provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic pharmaceuticals, preventive vaccines, diagnostic tools and consumer health products. Novartis is the only company with leading positions in these areas. In 2007, the Group’s continuing operations (excluding divestments in 2007) achieved net sales of USD 38.1 billion and net income of USD 6.5 billion. Approximately USD 6.4 billion was invested in R&D activities throughout the Group. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 97,000 full-time associates and operate in over 140 countries around the world. For more information, please visit http://www.novartis.com.
References
|
1. |
|
Blumenstein M, Romaszko J, Calderon A et al. Antihypertensive Efficacy And Tolerability of Aliskiren/Hydrochlorothiazide (HCTZ) Fixed-Dose Combination Tablets In Patients With Hypertension Who Are Not Adequately Responsive To HCTZ. Poster Presentation at American Society of Hypertension 23rd Annual Scientific Meeting 2008. |
|
2. |
|
Chobanian AV, Bakris GL, Black HR, et al. Seventh Report of the Joint National Committee on Prevention, Detection Evaluation and Treatment of High Blood Pressure. Hypertens 2003;42:1206-1251. |
|
3. |
|
SAFE. The European Patient Stroke (EPS) Survey 2006. Available at: http://www.safestroke.org/Default.aspx?tabid=312. Accessed November 3, 2008. |
|
4. |
|
Palatini P, Jung P, Schlyakhto E et al. Blood Pressure Reduction Following A Simulated Missed Dose Of Aliskiren, Irbesartan, or Ramipril: A Comparative Ambulatory Blood Pressure Monitoring Study. Poster Presentation at American Society of Hypertension 23rd Annual Scientific Meeting 2008. |
|
5. |
|
Oh BH, Mitchell J, Herron JR et al. Aliskiren, an Oral Renin Inhibitor, Provides Dose-Dependent Efficacy and Sustained 24-hour Blood Pressure Control in Patients with Hypertension. J Am Coll Cardiol 2007;49:1157-6. |
|
6. |
|
Rasilez HCT Swiss Prescribing Information. |
|
7. |
|
Tekturna HCT US Prescribing Information. |
# # #
4
Novartis Media Relations
|
Central media line : +41 61 324 2200 |
|
|
|
Eric Althoff Novartis Global Media Relations +41 61 324 7999 (direct) +41 79 593 4202 (mobile) eric.althoff@novartis.com |
|
Navjot Rai Novartis Pharma Communications +41 61 324 6498 (direct) +41 79 777 6400 (mobile) navjot.rai@novartis.com |
e-mail: media.relations@novartis.com
Novartis Investor Relations
|
Central phone: |
+41 61 324 7944 |
|
|
|
Ruth Metzler-Arnold |
+41 61 324 9980 |
North America: |
|
|
Pierre-Michel Bringer |
+41 61 324 1065 |
Richard Jarvis |
+1 212 830 2433 |
|
John Gilardi |
+41 61 324 3018 |
Jill Pozarek |
+1 212 830 2445 |
|
Thomas Hungerbuehler |
+41 61 324 8425 |
Edwin Valeriano |
+1 212 830 2456 |
|
Isabella Zinck |
+41 61 324 7188 |
|
|
|
|
|
|
|
|
e-mail: investor.relations@novartis.com |
e-mail: investor.relations@novartis.com |
||
5
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
|
Novartis AG |
||
|
|
|
|
||
|
|
|
|
||
|
Date: |
November 21, 2008 |
By: |
/s/ MALCOLM B. CHEETHAM |
|
|
|
|
|
||
|
|
|
Name: |
Malcolm B. Cheetham |
|
|
|
|
Title: |
Head Group Financial |
|
|
|
|
|
Reporting and Accounting |
|
6